Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 23,383 | 12,672 | -223,812 | -348,101 | -279,381 |
| Depreciation Amortization | -4,709 | 565 | 2,028 | 2,091 | 1,269 |
| Accounts receivable | -78,092 | -51,093 | 1,389 | -1,389 | N/A |
| Other Working Capital | -109,297 | -84,659 | -1,647 | -12,216 | -19,757 |
| Other Operating Activity | 128,198 | 91,102 | 45,872 | 63,981 | 83,362 |
| Operating Cash Flow | $-40,517 | $-31,413 | $-176,170 | $-295,634 | $-214,507 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 384 | -50,651 | -19,999 | 69 | -24,153 |
| PPE Investments | -45 | N/A | -14 | -401 | -357 |
| Purchase Of Investment | -1,375 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $-1,036 | $-50,651 | $-20,013 | $-332 | $-24,510 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 244,815 | 25,000 | N/A | 70,000 | N/A |
| Debt Repayment | -107,553 | N/A | -975 | -30,000 | N/A |
| Common Stock Issued | 914 | 47,830 | 584 | 2,435 | 679,827 |
| Common Stock Repurchased | -8,760 | N/A | N/A | N/A | N/A |
| Other Financing Activity | -889 | -125 | 0 | -1,016 | 0 |
| Financing Cash Flow | $128,527 | $72,705 | $-391 | $41,419 | $679,827 |
| Beginning Cash Position | 94,218 | 103,577 | 300,151 | 554,698 | 113,888 |
| End Cash Position | 181,192 | 94,218 | 103,577 | 300,151 | 554,698 |
| Net Cash Flow | $86,974 | $-9,359 | $-196,574 | $-254,547 | $440,810 |
| Free Cash Flow | |||||
| Operating Cash Flow | -40,517 | -31,413 | -176,170 | -295,634 | -214,507 |
| Capital Expenditure | -45 | N/A | -14 | -401 | -357 |
| Free Cash Flow | -40,562 | -31,413 | -176,184 | -296,035 | -214,864 |